ID: ALA219583

Max Phase: Preclinical

Molecular Formula: C29H26F4N6O2

Molecular Weight: 566.56

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CNc1nccc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)ccc3N3CCCCC3)c2)n1

Standard InChI:  InChI=1S/C29H26F4N6O2/c1-34-28-36-13-11-23(38-28)20-6-5-12-35-27(20)41-19-8-9-22(30)21(17-19)26(40)37-24-16-18(29(31,32)33)7-10-25(24)39-14-3-2-4-15-39/h5-13,16-17H,2-4,14-15H2,1H3,(H,37,40)(H,34,36,38)

Standard InChI Key:  RMOHLQRQXWWOMH-UHFFFAOYSA-N

Associated Targets(Human)

Vascular endothelial growth factor receptor 2 20924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tyrosine-protein kinase TIE-2 3348 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) 14 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus 775804 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 566.56Molecular Weight (Monoisotopic): 566.2053AlogP: 6.77#Rotatable Bonds: 7
Polar Surface Area: 92.27Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.65CX Basic pKa: 3.80CX LogP: 6.18CX LogD: 6.18
Aromatic Rings: 4Heavy Atoms: 41QED Weighted: 0.24Np Likeness Score: -1.76

References

1. Hodous BL, Geuns-Meyer SD, Hughes PE, Albrecht BK, Bellon S, Bready J, Caenepeel S, Cee VJ, Chaffee SC, Coxon A, Emery M, Fretland J, Gallant P, Gu Y, Hoffman D, Johnson RE, Kendall R, Kim JL, Long AM, Morrison M, Olivieri PR, Patel VF, Polverino A, Rose P, Tempest P, Wang L, Whittington DA, Zhao H..  (2007)  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.,  50  (4): [PMID:17253678] [10.1021/jm061107l]

Source